B
Braidwell Portfolio holdings
AUM
$2.92B
1-Year Return
4.59%
This Quarter Return
-7%
1 Year Return
-4.59%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$2.84B
AUM Growth
-$528M
(-16%)
Cap. Flow
-$1.18B
Cap. Flow
% of AUM
-41.6%
Top 10 Holdings %
Top 10 Hldgs %
40.1%
Holding
86
New
10
Increased
17
Reduced
14
Closed
17
Top Buys
| 1 |
Danaher
DHR
|
$63.4M |
| 2 |
argenx
ARGX
|
$47.4M |
| 3 |
Nuvalent
NUVL
|
$42.5M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$38.9M |
| 5 |
Krystal Biotech
KRYS
|
$36.1M |
Top Sells
| 1 |
Guardant Health
GH
|
$64.8M |
| 2 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$43.2M |
| 3 |
FNA
Paragon 28, Inc.
FNA
|
$39.6M |
| 4 |
BioNTech
BNTX
|
$35.3M |
| 5 |
Kiniksa Pharmaceuticals
KNSA
|
$33.1M |
Sector Composition
| 1 | Healthcare | 67.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Viking Therapeutics
VKTX
$2.98B
| $34.7M | 1.22% |
1,435,955
-43,711
| -3% | -$1.06M |
|
27
Penumbra
PEN
$10.9B
| $29.4M | 1.04% |
110,128
-73,700
| -40% | -$19.7M |
|
|
BCAX
28
Bicara Therapeutics Inc. Common Stock
BCAX
$658M
| $28.2M | 0.99% |
2,162,803
+162,144
| +8% | +$2.11M |
|
29
Day One Biopharmaceuticals
DAWN
$759M
| $28M | 0.99% |
3,536,853
-1,337,000
| -27% | -$10.6M |
|
30
OrthoPediatrics
KIDS
$519M
| $27.3M | 0.96% |
1,107,770
| – | – |
|
31
Harrow
HROW
$1.34B
| $25.5M | 0.89% |
956,839
+49,800
| +5% | +$1.32M |
|
32
Maravai LifeSciences
MRVI
$341M
| $18.5M | 0.65% |
8,353,287
| – | – |
|
33
Xencor
XNCR
$597M
| $17.6M | 0.62% |
1,655,690
+1,040,159
| +169% | +$11.1M |
|
34
Ascendis Pharma
ASND
$12B
| $16.6M | 0.58% |
+106,713
| New | +$16.6M |
|
|
ORKA
35
Oruka Therapeutics, Inc. Common Stock
ORKA
$561M
| $16.1M | 0.57% |
1,572,426
+424,750
| +37% | +$4.36M |
|
36
Madrigal Pharmaceuticals
MDGL
$9.61B
| $16.1M | 0.57% |
+48,690
| New | +$16.1M |
|
37
Sarepta Therapeutics
SRPT
$1.93B
| $15M | 0.53% |
234,500
-130,400
| -36% | -$8.32M |
|
38
Replimune Group
REPL
$454M
| $14.3M | 0.5% |
1,461,826
-15,276
| -1% | -$149K |
|
39
Repligen
RGEN
$6.78B
| $10.4M | 0.37% |
81,656
-202,167
| -71% | -$25.7M |
|
40
Ironwood Pharmaceuticals
IRWD
$179M
| $9.74M | 0.34% |
6,622,584
+1,182,307
| +22% | +$1.74M |
|
41
Celcuity
CELC
$2.31B
| $8.94M | 0.31% |
884,306
| – | – |
|
42
Cullinan Oncology
CGEM
$408M
| $7.42M | 0.26% |
980,773
-195,400
| -17% | -$1.48M |
|
43
Castle Biosciences
CSTL
$670M
| $7.31M | 0.26% |
+365,247
| New | +$7.31M |
|
44
Dianthus Therapeutics
DNTH
$794M
| $6.81M | 0.24% |
375,355
-831,234
| -69% | -$15.1M |
|
45
Pulmonx
LUNG
$70.9M
| $5.06M | 0.18% |
752,541
| – | – |
|
|
MTSR
46
Metsera, Inc. Common Stock
MTSR
$3.81B
| $4.76M | 0.17% |
+175,000
| New | +$4.76M |
|
|
AARD
47
Aardvark Therapeutics, Inc. Common Stock
AARD
$184M
| $3.76M | 0.13% |
+500,000
| New | +$3.76M |
|
|
JBIO
48
Jade Biosciences, Inc. Common Stock
JBIO
$254M
| $3.62M | 0.13% |
41,157
| – | – |
|
49
Zura Bio
ZURA
$135M
| $3.19M | 0.11% |
2,472,806
| – | – |
|
|
BBNX
50
Beta Bionics, Inc. Common Stock
BBNX
$874M
| $1.71M | 0.06% |
+140,000
| New | +$1.71M |
|